Grandfield & Dodd, LLC Nektar Therapeutics Transaction History

Grandfield & Dodd, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 03, 2022	SELL	$3.04 - $5.14 $26,596 - $44,969	-8,749 Reduced 25.88%	25,061 $80,000
Q2 2022 Aug 01, 2022	SELL	$3.17 - $6.17 $32,121 - $62,520	-10,133 Reduced 23.06%	33,810 $130,000
Q1 2022 Apr 19, 2022	BUY	$4.16 - $13.72 $13,936 - $45,962	3,350 Added 8.25%	43,943 $240,000
Q4 2021 Feb 08, 2022	BUY	$10.83 - $18.41 $115,556 - $196,434	10,670 Added 35.66%	40,593 $550,000
Q3 2021 Oct 28, 2021	BUY	$13.07 - $18.84 $24,375 - $35,136	1,865 Added 6.65%	29,923 $540,000
Q2 2021 Jul 28, 2021	BUY	$16.52 - $20.4 $14,042 - $17,340	850 Added 3.12%	28,058 $480,000
Q1 2021 Apr 22, 2021	BUY	$16.56 - $25.46 $36,432 - $56,012	2,200 Added 8.8%	27,208 $540,000
Q4 2020 Jan 29, 2021	BUY	$15.77 - $19.03 $32,643 - $39,392	2,070 Added 9.02%	25,008 $430,000
Q3 2020 Nov 03, 2020	BUY	$16.59 - $24.79 $8,344 - $12,469	503 Added 2.24%	22,938 $380,000
Q2 2020 Jul 24, 2020	BUY	$16.86 - $23.44 $61,539 - $85,556	3,650 Added 19.43%	22,435 $520,000
Q1 2020 May 14, 2020	BUY	$14.47 - $27.96 $44,350 - $85,697	3,065 Added 19.5%	18,785 $335,000
Q4 2019 Feb 07, 2020	BUY	$15.87 - $23.12 $249,476 - $363,446	15,720 New	15,720 $339,000

140

135M

32.8K

55.5K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $244M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Grandfield & Dodd, LLC, based on Form 13F filings with the SEC.

Stay updated on Grandfield & Dodd, LLC with notifications on news.